Stifel Nicolaus reissued their buy rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research report sent to investors on Friday. The brokerage currently has a $70.00 target price on the stock.

A number of other research analysts have also commented on AERI. BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, May 24th. HC Wainwright set a $69.00 price objective on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Saturday, April 15th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a hold rating to a strong-buy rating and set a $66.00 price objective on the stock in a research note on Monday, July 24th. Finally, ValuEngine upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $66.08.

Shares of Aerie Pharmaceuticals (AERI) opened at 54.30 on Friday. The stock’s market capitalization is $1.83 billion. The firm has a 50-day moving average of $54.19 and a 200 day moving average of $47.38. Aerie Pharmaceuticals has a 12-month low of $16.61 and a 12-month high of $59.50.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Equities analysts forecast that Aerie Pharmaceuticals will post ($2.56) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/aerie-pharmaceuticals-inc-aeri-stock-rating-reaffirmed-by-stifel-nicolaus/1465301.html.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 9.36% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB purchased a new position in shares of Aerie Pharmaceuticals during the first quarter worth about $3,311,000. Bank of New York Mellon Corp raised its position in shares of Aerie Pharmaceuticals by 34.8% in the first quarter. Bank of New York Mellon Corp now owns 265,076 shares of the company’s stock worth $12,021,000 after buying an additional 68,360 shares during the period. C WorldWide Group Holding A S raised its position in shares of Aerie Pharmaceuticals by 5.6% in the first quarter. C WorldWide Group Holding A S now owns 76,091 shares of the company’s stock worth $3,451,000 after buying an additional 4,008 shares during the period. Tocqueville Asset Management L.P. raised its position in shares of Aerie Pharmaceuticals by 19.8% in the first quarter. Tocqueville Asset Management L.P. now owns 90,900 shares of the company’s stock worth $4,122,000 after buying an additional 15,000 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Aerie Pharmaceuticals by 22.1% in the first quarter. Wells Fargo & Company MN now owns 26,273 shares of the company’s stock worth $1,191,000 after buying an additional 4,758 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.